The stem cell factor-c-kit system and mast cells in human pancreatic cancer

Laboratory Investigation

Volumn 82, Issue 11, 2002, Pages 1481-1492

  Esposito, Irene ^a,c   Kleeff, Jörg ^a   Bischoff, Stephan C ^b   Fischer, Lars ^a   Collecchi, Paola ^c   Iorio, Mariacarla ^c   Bevilacqua, Generoso ^c   Büchler, Markus W ^a   Friess, Helmut ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHYMASE; IMATINIB; STEM CELL FACTOR; TRYPTASE;

ACINAR CELL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; CYTOFLUOROMETRY; DOSE RESPONSE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; MAST CELL; PANCREAS CANCER; PANCREAS ISLET CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MAST CELLS; MIDDLE AGED; PANCREAS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; SERINE ENDOPEPTIDASES; STEM CELL FACTOR; TRYPTASES; TUMOR CELLS, CULTURED;

EID: 0036849231     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.LAB.0000036875.21209.F9     Document Type: Article

References (57)

1. Anderson DM, Lyman SD, Baird A, Wignall JM, Eisenman J, Rauch C, March CJ, Boswell HS, Gimpel SD, and Cosman D (1990). Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms. Cell 63:235-243.
2. Arber DA, Tamayo R, and Weiss LM (1998). Paraffin section detection of the c-kit gene product (CD117) in human tissues: Value in the diagnosis of mast cell disorders. Hum Pathol 29:498-504.
3. Bellone G, Silvestri S, Artusio E, Tibaudi D, Turletti A, Geuna M, Giachino C, Valente G, Emanuelli G, and Rodeck U (1997). Growth stimulation of colorectal carcinoma cells via the c-kit receptor is inhibited by TGF-beta 1. J Cell Physiol 172:1-11.
4. Besmer P, Murphy JE, George PC, Qiu FH, Bergold PJ, Lederman L, Snyder HW, Brodeur D, Zuckerman EE, and Hardy WD (1986). A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 320:415-421.
5. Bischoff SC and Dahinden CA (1992). c-kit ligand: A unique potentiator of mediator release by human lung mast cells. J Exp Med 175:237-244.
6. Bischoff SC, Schwengberg S, Raab R, and Manns MP (1997). Functional properties of human intestinal mast cells cultured in a new culture system: Enhancement of IgE receptor-dependent mediator release and response to stem cell factor. J Immunol 159:5560-5567.
7. Bischoff SC, Sellge G, Lorentz A, Sebald W, Raab R, and Manns MP (1999). IL-4 enhances proliferation and mediator release in mature human mast cells. Proc Natl Acad Sci USA 96:8080-8085.
8. Caruana G, Cambareri AC, Gonda TJ, and Ashman LK (1998). Transformation of NIH3T3 fibroblasts by the c-Kit receptor tyrosine kinase: Effect of receptor density and ligand-requirement. Oncogene 16:179-190.
9. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey GH, and Hanahan D (1999). Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 13: 1382-1397.
10. DiPaola RS, Kuczynski WI, Onodera K, Ratajczak MZ, Hijiya N, Moore J, and Gewirtz AM (1997). Evidence for a functional kit receptor in melanoma, breast, and lung carcinoma cells. Cancer Gene Ther 4:176-182.
11. Druker BJ and Lydon NB (2000). Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105:3-7.
12. Ebert M, Yokoyama M, Friess H, Kobrin MS, Buchler MW, and Korc M (1995). Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer. Int J Cancer 62:529-535.
13. Friess H, Yamanaka Y, Buchler M, Berger HG, Kobrin MS, Baldwin RL, and Korc M (1993a). Enhanced expression of the type II transforming growth factor beta receptor in human pancreatic cancer cells without alteration of type III receptor expression. Cancer Res 53:2704-2707.
14. Friess H, Yamanaka Y, Buchler M, Ebert M, Beger HG, Gold LI, and Korc M (1993b). Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 105:1846-1856.
15. Geissler EN, Ryan MA, and Housman DE (1988). The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell 55:185-192.
16. Hassan S, Kinoshita Y, Kawanami C, Kishi K, Matsushima Y, Ohashi A, Funasaka Y, Okada A, Maekawa T, He-Yao W, and Chiba T (1998). Expression of protooncogene c-kit and its ligand stem cell factor (SCF) in gastric carcinoma cell lines. Dig Dis Sci 43:8-14.
17. Huang S, Luca M, Gutman M, McConkey DJ, Langley KE, Lyman SD, and Bar-Eli M (1996). Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. Oncogene 13:2339-2347.
18. Huang E, Nocka K, Beier DR, Chu TY, Buck J, Lahm HW, Wellner D, Leder P, and Besmer P (1990). The hematopoietic growth factor KL is encoded by the SI locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell 63:225-233.
19. Imada A, Shijubo N, Kojima H, and Abe S (2000). Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. Eur Respir J 15:1087-1093.
20. Irani AA, Schechter NM, Craig SS, DeBlois G, and Schwartz LB (1986). Two types of human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci USA 83:4464-4468.
21. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, and Demetri GD (2001). Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052-1056.
22. Kankkunen JP, Harvima IT, and Naukkarinen A (1997). Quantitative analysis of tryptase and chymase containing mast cells in benign and malignant breast lesions. Int J Cancer 72:385-388.
23. Kleeff J, Maruyama H, Ishiwata T, Sawhney H, Friess H, Buchler MW, and Korc M (1999). Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology 116:1202-1216.
24. Konttinen YT, Hietanen J, Virtanen I, Ma J, Sorsa T, Xu JW, Williams NP, Manthorpe R, and Janin A (2000). Mast cell derangement in salivary glands in patients with Sjögren's syndrome. Rheumatol Int 19:141-147.
25. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M, and Beger HG (1992). Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest 90:1352-1360.
26. Krystal GW, Honsawek S, Litz J, and Buchdunger E (2000). The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 6:3319-3326.
27. Little SS and Johnson DA (1995). Human mast cell tryptase isoforms: Separation and examination of substrate-specificity differences. Biochem J 307:341-346.
28. Lu Z, Friess H, Graber HU, Guo X, Schilling M, Zimmermann A, Korc M, and Buchler MW (1997). Presence of two signaling TGF-beta receptors in human pancreatic cancer correlates with advanced tumor stage. Dig Dis Sci 42:2054-2063.
29. Lyman SD and Jacobsen SE (1998). c-kit ligand and Flt3 ligand: Stem/progenitor cell factors with overlapping yet distinct activities. Blood 91:1101-1134.
30. Majumder S, Brown K, Qiu FH, and Besmer P (1988). c-kit protein, a transmembrane kinase: Identification in tissues and characterization. Mol Cell Biol 8:4896-4903.
31. Majumder S, Ray P, and Besmer P (1990). Tyrosine protein kinase activity of the HZ4-feline sarcoma virus P80gag-kit-transforming protein. Oncogene Res 5:329-335.
32. Martin FH, Suggs SV, Langley KE, Lu HS, Ting J, Okino KH, Morris CF, McNiece IK, Jacobsen FW, and Mendiaz EA (1990). Primary structure and functional expression of rat and human stem cell factor DNAs. Cell 63:203-211.
33. Mauro MJ and Druker BJ (2001). Sti571: A gene product-targeted therapy for leukemia. Curr Oncol Rep 3:223-227.
34. Mauro MJ, O'Dwyer M, Heinrich MC, and Druker BJ (2002). STI571: A paradigm of new agents for cancer therapeutics. J Clin Oncol 20:325-334.
35. Moretti S, Pinzi C, Spallanzani A, Berti E, Chiarugi A, Mazzoli S, Fabiani M, Vallecchi C, and Herlyn M (1999). Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions. Int J Cancer 84:160-168.
36. Natali PG, Berlingieri MT, Nicotra MR, Fusco A, Santoro E, Bigotti A, and Vecchio G (1995). Transformation of thyroid epithelium is associated with loss of c-kit receptor. Cancer Res 55:1787-1791.
37. Natali PG, Nicotra MR, Sures I, Mottolese M, Botti C, and Ullrich A (1992). Breast cancer is associated with loss of the c-kit oncogene product. Int J Cancer 52:713-717.
38. Nishida K, Tsukamoto T, Uchida K, Takahashi T, and Ueda R (1996). Introduction of the c-kit gene leads to growth suppression of a breast cancer cell line, MCF-7. Anticancer Res 16:3397-3402.
39. Okuda K, Weisberg E, Gilliland DG, and Griffin JD (2001). ARG tyrosine kinase activity is inhibited by STI571. Blood 97:2440-2448.
40. Ozawa F, Friess H, Tempia-Caliera A, Kleeff J, and Buchler MW (2001). Growth factors and their receptors in pancreatic cancer. Teratog Carcinog Mutagen 21:27-44.
41. Pandiella A, Bosenberg MW, Huang EJ, Besmer P, and Massague J (1992). Cleavage of membrane-anchored growth factors involves distinct protease activities regulated through common mechanisms. J Biol Chem 267:24028-24033.
42. Parker SL, Tong T, Bolden S, and Wingo PA (1997). Cancer statistics, 1997. CA Cancer J Clin 47:5-27.
43. Pietsch T, Nicotra MR, Fraioli R, Wolf HK, Mottolese M, and Natali PG (1998). Expression of the c-Kit receptor and its ligand SCF in non-small-cell lung carcinomas. Int J Cancer 75:171-175.
44. Qiu FH, Ray P, Brown K, Barker PE, Jhanwar S, Ruddle FH, and Besmer P (1988). Primary structure of c-kit: Relationship with the CSF-1/PDGF receptor kinase family-oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO J 7:1003-1011.
45. Sandlow JI, Feng HL, and Sandra A (1997). Localization and expression of the c-kit receptor protein in human and rodent testis and sperm. Urology 49:494-500.
46. Takahashi T, Moyer MP, Cano M, Wang QJ, Adrian TE, Mountjoy CP, Sanger W, Sugiura H, Katoh H, and Pour PM (1995a). Establishment and characterization of a new, spontaneously immortalized, pancreatic ductal cell line from the Syrian golden hamster. Cell Tissue Res 282:163-174.
47. Takahashi T, Moyer MP, Cano M, Wang QJ, Mountjoy CP, Sanger W, Adrian TE, Sugiura H, Katoh H, and Pour PM (1995b). Differences in molecular biological, biological and growth characteristics between the immortal and malignant hamster pancreatic cells. Carcinogenesis 16:931-939.
48. Takanami I, Takeuchi K, and Naruke M (2000). Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer 88:2686-2692.
49. Tonary AM, Macdonald EA, Faught W, Senterman MK, and Vanderhyden BC (2000). Lack of expression of c-KIT in ovarian cancers is associated with poor prognosis. Int J Cancer 89:242-250.
50. Toyota M, Hinoda Y, Itoh F, Takaoka A, Imai K, and Yachi A (1994). Complementary DNA cloning and characterization of truncated form of c-kit in human colon carcinoma cells. Cancer Res 54:272-275.
51. Tsuura Y, Hiraki H, Watanabe K, Igarashi S, Shimamura K, Fukuda T, Suzuki T, and Seito T (1994). Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: Immunohistochemical study on formalin-fixed, paraffin-embedded tissues. Virchows Arch 424:135-141.
52. Valent P, Spanblochl E, Sperr WR, Sillaber C, Zsebo KM, Agis H, Strobl H, Geissler K, Bettelheim P, and Lechner K (1992). Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. Blood 80:2237-2245.
53. Welker P, Schadendorf D, Artuc M, Grabbe J, and Henz BM (2000). Expression of SCF splice variants in human melanocytes and melanoma cell lines: Potential prognostic implications. Br J Cancer 82:1453-1458.
54. Witte ON (1990). Steel locus defines new multipotent growth factor. Cell 63:5-6.
55. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG, and Korc M (1993). Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 13:565-569.
56. Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U, and Ullrich A (1987). Human proto-oncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 6:3341-3351.
57. Zhang S, Anderson DF, Bradding P, Coward WR, Baddeley SM, MacLeod JD, McGill JI, Church MK, Holgate ST, and Roche WR (1998). Human mast cells express stem cell factor. J Pathol 186:59-66.